{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:18:03Z","timestamp":1788880683034,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jchromb.2022.123275","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:00:22Z","timestamp":1651651222000},"page":"123275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry"],"prefix":"10.1016","volume":"1200","author":[{"given":"Sha","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-ping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-ying","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2022.123275_b0005","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin. Can. Res."},{"key":"10.1016\/j.jchromb.2022.123275_b0010","doi-asserted-by":"crossref","unstructured":"K. Tang, A.C. Schuh, K.Wl., Yee, 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye? Curr. Oncol. Rep. 23 (2021) 120.","DOI":"10.1007\/s11912-021-01108-9"},{"key":"10.1016\/j.jchromb.2022.123275_b0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jconrel.2021.08.023","article-title":"Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351","volume":"338","author":"Donnette","year":"2021","journal-title":"J. Control Release"},{"key":"10.1016\/j.jchromb.2022.123275_b0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2006.12.002","article-title":"Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?","volume":"118","author":"Cui","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jchromb.2022.123275_b0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jchromb.2017.11.020","article-title":"Determination of non-liposomal and liposomal doxorubicin in plasma by LC\u2013MS\/MS coupled with an effective solid phase extraction: In comparison with ultrafiltration technique and application to a pharmacokinetic study","volume":"1072","author":"Xie","year":"2018","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2022.123275_b0030","unstructured":"Food and Drug Administration, Draft Guidance on Doxorubicin Hydrochloride, Recommended Feb 2010, Revised Nov 2013, Dec 2014, Apr 2017, Sept 2018."},{"key":"10.1016\/j.jchromb.2022.123275_b0035","unstructured":"Food and Drug Administration, Liposome drug products: chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation, 2018."},{"key":"10.1016\/j.jchromb.2022.123275_b0040","unstructured":"Food and Drug Administration, 2017, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209401s000lbl.pdf."},{"key":"10.1016\/j.jchromb.2022.123275_b0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.jchromb.2022.123275_b0050","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1002\/jps.21620","article-title":"Pharmacokinetics of CPX-351 (cytarabine\/daunorubicin HCl) liposome injection in the mouse","volume":"98","author":"Bayne","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2022.123275_b0055","article-title":"Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals","volume":"30","author":"Wang","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jchromb.2022.123275_b0060","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jpba.2018.06.014","article-title":"Bioanalysis of free and liposomal Amphotericin B in rat plasma using solid phase extraction and protein precipitation followed by LC-MS\/MS","volume":"158","author":"Su","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"11","key":"10.1016\/j.jchromb.2022.123275_b0065","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.2042-7158.1996.tb03904.x","article-title":"Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods","volume":"48","author":"Dipali","year":"1996","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.jchromb.2022.123275_b0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/abio.1995.0001","article-title":"Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques","volume":"232","author":"Mayer","year":"1995","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jchromb.2022.123275_b0075","doi-asserted-by":"crossref","unstructured":"R. Bellott, Pouna, Jacques Robert. Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome, J. Chromatogr. B. 757 (2001) 257-267.","DOI":"10.1016\/S0378-4347(01)00151-7"},{"issue":"3","key":"10.1016\/j.jchromb.2022.123275_b0080","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00280-013-2369-5","article-title":"Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs","volume":"73","author":"Zhong","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2022.123275_b0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2019.03.034","article-title":"A validated UPLC-MS\/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection","volume":"170","author":"Zhuang","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2022.123275_b0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jchromb.2008.05.033","article-title":"High performance liquid chromatography\u2013tandem mass spectrometry method for the simultaneous determination of cytarabine and its valyl prodrug valcytarabine in rat plasma","volume":"870","author":"Sun","year":"2008","journal-title":"J. Chromatogr. B"},{"issue":"14","key":"10.1016\/j.jchromb.2022.123275_b0095","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.4155\/bio.11.140","article-title":"HPLC\u2013MS\/MS method for the determination of cytarabine in human plasma","volume":"3","author":"Hilhorst","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2022.123275_b0100","unstructured":"US Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, 2018, https:\/\/www.fda.gov\/media\/70858\/download."},{"key":"10.1016\/j.jchromb.2022.123275_b0105","unstructured":"European Medicines Agency, Guideline on Bioanalytical Method Validation, 2011, http:\/\/www.ema.europa.eu\/docs\/en.GB\/documentlibrary\/Scientificguideline\/2011\/08\/WC500109686.pdf."},{"issue":"3-4","key":"10.1016\/j.jchromb.2022.123275_b0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jchromb.2009.11.036","article-title":"Determination of free and liposomal Amphotericin B in human plasma by liquid chromatography\u2013mass spectroscopy with solid phase extraction and protein precipitation techniques","volume":"878","author":"Deshpande","year":"2010","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2022.123275_b0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chroma.2012.12.026","article-title":"Determination of free and totalvincristine in human plasma after intravenous administration of vincristinesulfate liposome injection using ultra-high performance liquidchromatography tandem mass spectrometry","volume":"1275","author":"Yang","year":"2013","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2022.123275_b0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1099\/13500872-142-2-269","article-title":"The dnrM gene in Streptomyces peucetius contains a naturally occurring frameshift mutation that is suppressed by another locus outside of the daunorubicin-production gene cluster","volume":"142","author":"Gallo","year":"1996","journal-title":"Microbiology"},{"issue":"5","key":"10.1016\/j.jchromb.2022.123275_b0125","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1517\/17425255.2015.985648","article-title":"Role of cytidine deaminase in toxicity andefficacy of nucleosidic analogs","volume":"11","author":"Serdjebi","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jchromb.2022.123275_b0130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpba.2015.12.049","article-title":"HPLC-MS\/MS method for the simultaneous determination of MB07133 and its metabolites, cytarabine and arabinofuranosyluracil, in rat plasma","volume":"120","author":"Wang","year":"2016","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023222001799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023222001799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:08:23Z","timestamp":1761606503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023222001799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":26,"alternative-id":["S1570023222001799"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2022.123275","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2022.123275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123275"}}